These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16691018)

  • 1. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL.
    Holtser-Cochav M; Divinski I; Gozes I
    J Mol Neurosci; 2006; 28(3):303-7. PubMed ID: 16691018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).
    Gozes I; Divinski I; Piltzer I
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S3. PubMed ID: 19091000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
    Gozes I; Iram T; Maryanovsky E; Arviv C; Rozenberg L; Schirer Y; Giladi E; Furman-Assaf S
    J Alzheimers Dis; 2014; 40 Suppl 1():S23-36. PubMed ID: 24503616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-SAL and NAP: Two Peptides Sharing a SIP Domain.
    Gozes I; Sragovich S; Schirer Y; Idan-Feldman A
    J Mol Neurosci; 2016 Jun; 59(2):220-31. PubMed ID: 26816081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide neuroprotection through specific interaction with brain tubulin.
    Divinski I; Holtser-Cochav M; Vulih-Schultzman I; Steingart RA; Gozes I
    J Neurochem; 2006 Aug; 98(3):973-84. PubMed ID: 16893427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
    Shiryaev N; Pikman R; Giladi E; Gozes I
    Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effect of the peptides ADNF-9 and NAP on hypoxic-ischemic brain injury in neonatal rats.
    Kumral A; Yesilirmak DC; Sonmez U; Baskin H; Tugyan K; Yilmaz O; Genc S; Gokmen N; Genc K; Duman N; Ozkan H
    Brain Res; 2006 Oct; 1115(1):169-78. PubMed ID: 16938277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotrophic peptides, ADNF-9 and NAP, prevent alcohol-induced apoptosis at midgestation in fetal brains of C57BL/6 mouse.
    Sari Y; Weedman JM; Nkrumah-Abrokwah M
    J Mol Neurosci; 2013 Jan; 49(1):150-6. PubMed ID: 23229836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis.
    Busciglio J; Pelsman A; Helguera P; Ashur-Fabian O; Pinhasov A; Brenneman DE; Gozes I
    Curr Pharm Des; 2007; 13(11):1091-8. PubMed ID: 17430172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.
    Oz S; Ivashko-Pachima Y; Gozes I
    PLoS One; 2012; 7(12):e51458. PubMed ID: 23272107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures.
    Smith-Swintosky VL; Gozes I; Brenneman DE; D'Andrea MR; Plata-Salaman CR
    J Mol Neurosci; 2005; 25(3):225-38. PubMed ID: 15800376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell.
    Gozes I; Divinski I
    Curr Alzheimer Res; 2007 Dec; 4(5):507-9. PubMed ID: 18220512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.
    Gozes I; Divinski I
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S37-41. PubMed ID: 15665412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-mediated protection from ethanol-induced neural tube defects.
    Chen SY; Charness ME; Wilkemeyer MF; Sulik KK
    Dev Neurosci; 2005; 27(1):13-9. PubMed ID: 15886480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide antagonists of ethanol inhibition of l1-mediated cell-cell adhesion.
    Wilkemeyer MF; Menkari CE; Spong CY; Charness ME
    J Pharmacol Exp Ther; 2002 Oct; 303(1):110-6. PubMed ID: 12235240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.
    Gozes I; Giladi E; Pinhasov A; Bardea A; Brenneman DE
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1091-8. PubMed ID: 10869414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate.
    Gozes I; Spivak-Pohis I
    Curr Alzheimer Res; 2006 Jul; 3(3):197-9. PubMed ID: 16842095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective peptides that are orally active and mechanistically nonchiral.
    Brenneman DE; Spong CY; Hauser JM; Abebe D; Pinhasov A; Golian T; Gozes I
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1190-7. PubMed ID: 15007105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethanol antagonist peptides: structural specificity without stereospecificity.
    Wilkemeyer MF; Chen SY; Menkari CE; Sulik KK; Charness ME
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1183-9. PubMed ID: 14762101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors.
    Vink J; Incerti M; Toso L; Roberson R; Abebe D; Spong CY
    Am J Obstet Gynecol; 2009 May; 200(5):524.e1-4. PubMed ID: 19327737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.